Co-Diagnostics, Inc. (CODX)
Chart Events
Performance Outlook
| Previous Close | 4.3100 |
| Open | 4.2300 |
| Bid | 4.1200 x 1300 |
| Ask | 4.1300 x 1100 |
| Day's Range | 4.0700 - 4.2800 |
| 52 Week Range | 3.6600 - 11.8200 |
| Volume | |
| Avg. Volume | 632,740 |
| Market Cap | 139.684M |
| Beta (5Y Monthly) | -1.00 |
| PE Ratio (TTM) | 4.75 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for CODX
Related Research
- Co-Diagnostics, Inc.Analyst Report: Johnson & JohnsonJohnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. Geographically, just over half of total revenue is generated in the United States.RatingFair ValueEconomic Moat8 days agoMorningstar
- Motley Fool
Why Co-Diagnostics Stock Slipped Today
An analyst price target cut was the impetus behind Co-Diagnostics' (NASDAQ: CODX) share price drop on Monday. The biotech's stock lost nearly 4% of its value that day; what didn't help was that the cut was preceded by a recommendation downgrade from a different prognosticator. Co-Diagnostics is now worth $9 per share, in the estimation of H.C. Wainwright's Raghuram Selvaraju.
- Benzinga
Co-Diagnostics Looks To Expand Monkeypox Testing Amid Falling COVID-19 Test Revenues
Co-Diagnostics Inc (NASDAQ: CODX) posted Q2 revenue of $5 million, down from $27.4 million a year ago, way below the consensus of $20.5 million, primarily due to lower demand for the Logix Smart COVID-19 Test. The company posted an operating loss of $(4.1) million compared to an operating income of $11.8 million a year ago due to lower sales volumes and continued investments in R&D. Co-Diagnostics recorded an EPS loss of $(0.08), a shift from an EPS income of $0.33, missing the consensus of $0.1
- Motley Fool
Why Shares of Co-Diagnostics Stock Fell 10% on Tuesday
What happened Co-Diagnostics (NASDAQ: CODX), a maker of molecular diagnostics tests, fell 10% on Tuesday. The stock closed at $7.01 a share on Monday, then opened at $6.95 on Wednesday before dropping to a low of $6.
